Patient characteristics | Finnish cohort | Swedish cohort | |
---|---|---|---|
n = 65 | n = 82 | p-value | |
Age (y); mean (SD) | 72.4 (7.4) | 73.0 (7.2) | 0.60 |
Male sex; n (%) | 37 (57) | 53 (65) | 0.34 |
Weight (kg); mean (SD) | 79.2 (15.4) | 79.2 (19.8) | 0.99 |
Height (cm); mean (SD) | 168.4 (7.8) | 169.1 (18.8) | 0.79 |
Diabetes mellitus T2; n (%) | 24 (38) | 19 (24) | 0.099 |
Hypertonia; n (%) | 41 (63) | 44 (54) | 0.29 |
Cardiac disease; n (%) | 21 (32) | 26 (32) | 0.98 |
MMSE; mean (SD) | |||
Pre-op | 22.6 (4.2) | 23.6 (4.4) | 0.16 |
Post-op | 22.8 (5.4) | 23.9 (5.7) | 0.22 |
Gait velocity (m/s); mean (SD) | |||
Pre-op | 0.60 (0.26) | 0.66 (0.27) | 0.26 |
Post-op | 0.80 (0.31) | 0.84 (0.36) | 0.51 |
APOE- genotype; n (%) | 0.32 | ||
ε2/ε2 | 0 (0) | 1 (1.9) | |
ε2/ε3 | 7 (10.9) | 5 (9.3) | |
ε2/ε4 | 3 (4.7) | 4 (7.4) | |
ε3/ε3 | 42 (65.6) | 26 (48.1) | |
ε3/ε4 | 10 (15.6) | 16 (29.6) | |
ε4/ε4 | 2 (3.1) | 2 (3.7) | |
NPHGS improvement; n (%) | 34 (52) | ||
NPHS improvement; n (%) | 48 (59) |
Biomarkers | |||
---|---|---|---|
T-tau (ng/l); mean (SD) | 222.0 (111.4) | 244.9 (130.5) | 0.28 |
P-tau (ng/l); mean (SD) | 30.5 (12.2) | 31.9 (12.4) | 0.50 |
NfL (ng/l); mean (SD) | 1573.8 (1661.5) | 1717.3 (1962.8) | 0.64 |
Aβ38 (ng/l); mean (SD) | 1471.4 (515.0) | 1526.0 (518.9) | 0.53 |
Aβ40 (ng/l); mean (SD) | 3697.5 (1161.4) | 3799.8 (1193.5) | 0.60 |
Aβ42 (ng/l); mean (SD) | 367.4 (151.4) | 364.3 (137.8) | 0.90 |
sAPPα (ng/l); mean (SD) | 416.6 (212.7) | 446.2 (177.6) | 0.37 |
sAPPβ (ng/l); mean (SD) | 305.2 (142.2) | 321.0 (121.1) | 0.47 |
MCP1 (ng/l); mean (SD) | 463.2 (122.1) | 492.2 (109.4) | 0.13 |